Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496967 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2024013725 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual aggregation based joint-modal similarity hashing for cross-modal retrieval.
Neural Netw
September 2025
Shanghai Maritime University, Shanghai, 201306, China. Electronic address:
Cross-modal hashing aims to leverage hashing functions to map multimodal data into a unified low-dimensional space, realizing efficient cross-modal retrieval. In particular, unsupervised cross-modal hashing methods attract significant attention for not needing external label information. However, in the field of unsupervised cross-modal hashing, there are several pressing issues to address: (1) how to facilitate semantic alignment between modalities, and (2) how to effectively capture the intrinsic relationships between data, thereby constructing a more reliable affinity matrix to assist in the learning of hash codes.
View Article and Find Full Text PDFThe barriers for uptake of artificial intelligence in hepatology and how to overcome them.
J Hepatol
July 2025
Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany; Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, 01307 Dresden, Germany; Medical Oncology, National Center for Tumor Disease
Artificial intelligence (AI) methods in hepatology have proliferated since the mid-2010s, with numerous publications and some regulatory approvals. Yet, adoption of AI methods in real-world clinical practice and clinical research remains limited. Despite clear benefits of using AI to analyze complex data types in hepatology, such as histopathology, radiology images, multi-omics and more recently, natural language patient data, there are still substantial barriers and challenges to its integration into routine clinical workflows.
View Article and Find Full Text PDFDiscovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
J Med Chem
September 2025
Applied Pharmaceutical Science, Inc., Building 10-1, No.2, Jingyuan North Street, BDA, Beijing 100176, China.
This study reports the discovery and preclinical activity of APS03118, a novel selective RET inhibitor featuring a novel tricyclic pyrazolo[3',4':3,4]pyrazolo[1,5-]pyridine hinge-binding scaffold designed to overcome acquired resistance to first-generation selective RET inhibitors (SRIs). By enhancing hydrogen bonding with conserved hinge residues (Glu805, Ala807), APS03118 potently inhibits wild-type RET and diverse resistance mutations, including solvent-front (G810R/S/C), gatekeeper (V804M/L/E), roof (L730I/M), and hinge (Y806C/N/H) variants. In preclinical models, APS03118 induced complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient-derived xenografts (PDXs) and significantly prolonged survival in an intracranial CCDC6-RET metastasis model.
View Article and Find Full Text PDFSystematic engineering of TROP2-targeted CAR T-cell therapy overcomes resistance pathways in solid tumors.
Cancer Immunol Res
September 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include: down-regulation of the target antigen; mutation of the target epitope; or in the case of antibody drug conjugates (ADCs), resistance to the chemotherapy warhead. Since TROP2-targeted therapy with ADCs yields responses in TROP2+ solid tumors but lacks the durability observed with other immunotherapy-based approaches, we developed novel TROP2-targeting chimeric antigen receptor (CAR) T cells as an alternative.
View Article and Find Full Text PDFLimiting viral replication in hematopoietic cells delays Rift Valley fever virus disease progression in C57BL/6 mice.
J Virol
September 2025
Division of Pediatric Infectious Disease, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Rift Valley fever virus (RVFV) causes mild to severe disease in livestock and humans. It was first identified in 1931 during an epizootic in Kenya and has spread across Africa and into the Middle East. Hematopoietic cells are one of the major targets of RVFV ; however, their contribution to RVFV pathogenesis remains poorly understood.
View Article and Find Full Text PDF